PZ Wind Down

PZRXQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed · Aug 26, 1:06 PM ET

No price history for this range.

About PZRXQ

PhaseRx, Inc. operates as a bio pharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. The firm's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The firm's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The firm is headquartered in Seattle.

Employees: 0
Headquarters: Seattle, Washington
Listed: May 18, 2016
Sector: Health Care
Industry: Biotechnology

Leadership

PZ Wind Down executives
Name	Title	Since	Age
Steven Gillis	—	—	71
Robert Overell	—	—	62
Sean Monahan	—	—	—
Mary Prieve	—	—	—
Gordon Brandt	—	—	57
James Watson	—	—	—
Paul Johnson	—	2007	73
Brian Atwood	—	—	71
Michelle Griffin	—	—	51
Peggy Phillips	—	—	70
John Schmidt	—	—	66
Erin Cox	—	2015	—

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

PZ Wind Down suppliers and customers
Company	Relationship	Country	Correlation
TriLink BioTechnologies LLC	Supplier and customer	US	—
University of Washington	Supplier and customer	US	—

Similar companies

Companies in the same industry as PZ Wind Down

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.